| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Fisetin (Fustel; CCRIS9034; NSC40701; 3, 7, 3′, 4′-tetrahydroxyflavone) is a naturally occuring and dietary flavonoid isolated from/found in a variety of fruits and vegetables (i.e. strawberries, apples, persimmons, onions and cucumbers). It has many important biological activity including anti-inflammatory, anti-oxidant, anti-diabetic, anti-invasive, anti-tumorigenic, neuroprotective, anti-angiogenic, and cardioprotective effects in cell culture and in animal models relevant to human diseases. It is a potent sirtuin activating compound (STAC) and an agent that modulates sirtuins. It also acts as a tubulin inhibitor/stabilizer. Fisetin is a structurally distinct chemical belonging to the flavonoid class of polyphenols.
| ln Vitro |
Fisetin reduces lipid accumulation and lowers PPARγ expression in 3T3-L1 cells. Fisetin suppresses early phases of preadipocyte development and stimulates Sirt1 expression. Fisetin stimulates Sirt1-mediated deacetylation of PPARγ and FoxO1, boosts the binding of Sirt1 to the PPARγ promoter, consequently decreasing PPARγ transcriptional activity, thereby inhibiting adipogenesis [1]. Fisetin binds tubulin and stabilizes microtubules, having binding properties substantially superior to those of paclitaxel. Fisetin treatment of human prostate cancer cells resulted in substantial overexpression of microtubule-associated proteins (MAP)-2 and -4. Fisetin strongly suppresses PCa cell growth, migration and invasion. Nudc, a protein linked with the microtubule motor dynein/dynamin complex that governs microtubule dynamics, is inhibited by Fisetin therapy [2].
|
||
|---|---|---|---|
| ln Vivo |
Treatment with fisetin decreased inflammatory cell infiltration and proliferation in mice exposed to UVB rays. Additionally, treating with fisetin lowers the levels of inflammatory mediators like COX-2, PGE2 and its receptors (EP1–EP4), and MPO activity. Moreover, fisetin lowers UVB-exposed skin's concentrations of the inflammatory cytokines TNFα, IL-1β, and IL-6. Increased expression of the proteins p53 and p21 indicates that fisetin treatment also reduces DNA damage and markers of cell proliferation [3].
|
||
| Animal Protocol |
|
||
| References |
[1]. Kim SC, et al. Fisetin induces Sirt1 expression while inhibiting early adipogenesis in 3T3-L1 cells. Biochem Biophys Res Commun. 2015 Nov 27;467(4):638-44.
[2]. Mukhtar E, et al. Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells. Cancer Lett. 2015 Oct 28;367(2):173-83 |
| Molecular Formula |
C15H10O6
|
|
|---|---|---|
| Molecular Weight |
286.24
|
|
| CAS # |
528-48-3
|
|
| Related CAS # |
Fisetin quarterhydrate;Fisetin (Standard);528-48-3
|
|
| SMILES |
O1C2C([H])=C(C([H])=C([H])C=2C(C(=C1C1C([H])=C([H])C(=C(C=1[H])O[H])O[H])O[H])=O)O[H]
|
|
| InChi Key |
XHEFDIBZLJXQHF-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C15H10O6/c16-8-2-3-9-12(6-8)21-15(14(20)13(9)19)7-1-4-10(17)11(18)5-7/h1-6,16-18,20H
|
|
| Chemical Name |
2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 10 mg/mL (34.94 mM) in 45% PEG300 5% Tween-80 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4936 mL | 17.4679 mL | 34.9357 mL | |
| 5 mM | 0.6987 mL | 3.4936 mL | 6.9871 mL | |
| 10 mM | 0.3494 mL | 1.7468 mL | 3.4936 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06133634 | Recruiting | Dietary Supplement: Fisetin Other: Placebo |
Aging Endothelial Dysfunction |
University of Colorado, Boulder | September 25, 2023 | Phase 1 Phase 2 |
| NCT05416515 | Recruiting | Drug: Fisetin | Carpal Tunnel Syndrome | Peter C. Amadio, M.D. | October 9, 2022 | Phase 2 |
| NCT05595499 | Recruiting | Procedure: Biospecimen Collection Drug: Fisetin |
Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 |
Jonsson Comprehensive Cancer Center | March 27, 2023 | Phase 2 |
| NCT04537299 | Active, not recruiting | Drug: Fisetin Drug: Placebo |
Covid19 SARS-CoV Infection |
Mayo Clinic | April 29, 2022 | Phase 2 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
